In developing this automated cell therapy processing platform, Limula’s founders aim to create a disruptive production ...

Dr. Radhakrishnan brings significant experience in product development and commercialization that will be particularly valuable as Candel prepares for its Biologics License Application (BLA) ...

Shares of the biotech Kymera Therapeutics are up 50% since Monday, when data from an early trial hinted that its pill might ...

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ...

For people diagnosed with macular telangiectasia type 2 (MacTel)—a rare and slowly progressing retinal disease—there have ...

TAO price holds steady around $410–$420 in June 2025 as Bittensor expands AI subnets and gains institutional support.

Axplora’s Chasse-sur-Rhône CDMO site in France has successfully passed its latest on-site inspection by the ANSM.

Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI ® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ...

The CDMO's head of development talks about ADCs, accelerated timelines, and the push for end-to-end development services.

AI will deliver transformative therapies at an exponential scale, addressing the complexities of biology that traditional ...

CAMBRIDGE, MASS. — The US Department of Health and Human Services (HHS) notified pharmaceutical company Moderna Inc. on May ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...